Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

A chemical screen identifies novel compounds that overcome glial-mediated inhibition of neuronal regeneration.

The Journal of neuroscience : the official journal of the Society for Neuroscience | 2010

A major barrier to regeneration of CNS axons is the presence of growth-inhibitory proteins associated with myelin and the glial scar. To identify chemical compounds with the ability to overcome the inhibition of regeneration, we screened a novel triazine library, based on the ability of compounds to increase neurite outgrowth from cerebellar neurons on inhibitory myelin substrates. The screen produced four "hit compounds," which act with nanomolar potency on several different neuronal types and on several distinct substrates relevant to glial inhibition. Moreover, the compounds selectively overcome inhibition rather than promote growth in general. The compounds do not affect neuronal cAMP levels, PKC activity, or EGFR (epidermal growth factor receptor) activation. Interestingly, one of the compounds alters microtubule dynamics and increases microtubule density in both fibroblasts and neurons. This same compound promotes regeneration of dorsal column axons after acute lesions and potentiates regeneration of optic nerve axons after nerve crush in vivo. These compounds should provide insight into the mechanisms through which glial-derived inhibitors of regeneration act, and could lead to the development of novel therapies for CNS injury.

Pubmed ID: 20357120 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: NS063593
  • Agency: NEI NIH HHS, United States
    Id: EY014801
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS061348-02
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD057632
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS061348-01A2
  • Agency: NINDS NIH HHS, United States
    Id: F31 NS063593
  • Agency: NINDS NIH HHS, United States
    Id: NS061348
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS059866
  • Agency: NINDS NIH HHS, United States
    Id: NS059866
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS061348-04
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS061348
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS059866-02
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS059866-01A2
  • Agency: NEI NIH HHS, United States
    Id: P30 EY014801
  • Agency: NICHD NIH HHS, United States
    Id: HD057632
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS061348-03

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


tubulin beta (antibody)

RRID:AB_528499

This unknown targets

View all literature mentions